Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17243378 | 0.92 | MET (0.56) | METGAA | |
| SCHEMBL12501023 | 0.91 | MET (0.55) | METGAA | |
| SCHEMBL12410771 | 0.86 | GAA (0.62) | METGAA | |
| SCHEMBL17243366 | 0.82 | MET (0.60) | METGAA | |
| SCHEMBL17243372 | 0.80 | GAA (0.58) | METGAA | |
| SCHEMBL12495023 | 0.79 | MET (0.60) | METGAA | |
| SCHEMBL12410825 | 0.77 | MET (0.54) | METGAA | |
| SCHEMBL12499993 | 0.76 | MET (0.67) | METGAA | |
| SCHEMBL1558452 | 0.74 | MET (0.60) | METGAA | |
| SCHEMBL17243374 | 0.71 | MET (0.60) | METGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-9181199-B2 | Uracil derivatives and use thereof | RESPROTECT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | TYMP, UNG, DPYD | MET 4164/4885GAA 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.